Founded in 2020, Sudo's lead programs target the TYK2 pseudokinase domain. TYK2 is a key mediator in cytokine signaling pathways that have been linked to a broad range of immune-mediated inflammatory conditions. Inhibiting TYK2 has been shown to be beneficial in the treatment of psoriasis, psoriatic arthritis, and lupus. Additional evidence suggests that TYK2 inhibition could provide benefit in an even broader range of autoimmune disorders such as ulcerative colitis, Crohn's disease, ankylosing spondylitis, multiple sclerosis, and others.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 09/28/22 | $37,000,000 | Series A |
Frazier Healthcare Partners Velosity Capital | undisclosed |
| 12/20/23 | $116,000,000 | Series B |
Enavate Sciences Eventide Asset Management Frazier Life Sciences Monograph Capital Sanofi Ventures Surveyor Capital TPG Velosity Capital | undisclosed |
| 02/13/24 | $30,000,000 | Series B |
Dementia Discovery Fund Leaps by Bayer UPMC Enterprises | undisclosed |
